Continuous or Intermittent Dosing With Sertraline for Patients With Severe Premenstrual Syndrome or Premenstrual Dysphoric Disorder
Authors:
- Ellen W. FreemanEFEllen W. Freeman
- Karl RickelsKRKarl Rickels
- Steven J. SondheimerSSSteven J. Sondheimer
- Marcia PolanskyMPMarcia Polansky
- Sha XiaoSXSha Xiao
- 1 February 2004
- journal article
- clinical trial
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 161 (2) , 343-351
Abstract
The authors compared the efficacy and acceptability of continuous versus intermittent treatment with a selective serotonin reuptake inhibitor in women with severe premenstrual syndrome and determined the effects of postmenstrual symptom severity and depression history as covariates of the treatment response. Patients who met symptom criteria and reported impaired functioning after three screening cycles were randomly assigned to three cycles of double-blind, placebo-controlled treatment with continuous (full-cycle dosing) or intermittent (luteal-phase dosing) sertraline. The design was stratified for severity of postmenstrual symptoms and history of major depression. Flexible sertraline dose was 50-100 mg/day. Outcome measures were the Daily Symptom Rating Form score and patient global ratings of functioning. Both sertraline groups improved significantly more than the placebo group as assessed by total premenstrual Daily Symptom Rating Form scores for 3 treatment months. Daily Symptom Rating Form factors that were significantly more improved in the sertraline groups were mood and physical symptoms. Sertraline improvement occurred swiftly in the first month of treatment. Gradual placebo improvement was similar to sertraline in the third month. Subjects with higher postmenstrual symptoms before treatment remained more symptomatic regardless of the dosing regimen. A history of major depression was not associated with treatment response. More sertraline-treated subjects reported improved functioning in the domains of family relationships, social activities, and sexual activity. Premenstrual dosing does not differ from continuous dosing with sertraline in premenstrual syndrome treatment. Higher levels of postmenstrual symptoms limit treatment response and are important to define in treatment of premenstrual syndrome.Keywords
This publication has 37 references indexed in Scilit:
- Operationalizing DSM-IV criteria for PMDD: selecting symptomatic and asymptomatic cycles for researchJournal of Psychiatric Research, 2003
- Medical (fluoxetine) and psychological (cognitive–behavioural therapy) treatment for premenstrual dysphoric disorderJournal of Psychosomatic Research, 2002
- Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placeboPsychopharmacology, 2001
- Differential Response to Antidepressants in Women With Premenstrual Syndrome/Premenstrual Dysphoric DisorderArchives of General Psychiatry, 1999
- Luteal Phase Sertraline Treatment for Premenstrual Dysphoric Disorder: Results of a Double-blind, Placebo-Controlled, Crossover StudyArchives of Family Medicine, 1999
- Cognitive therapy for premenstrual syndromeJournal of Psychosomatic Research, 1998
- Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group1997
- Placebo EffectsPsychosomatics, 1996
- A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome1995
- Placebo Effect—How Powerful?Fertility and Sterility, 1993